This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jun 2, 2026
•
4 min read
🧬 Moderna, Merck & Co.'s (intismeran autogene) plus Keytruda shows 49% recurrence risk reduction in Ph2b high-risk melanoma, Bristol Myers Squibb's (izalontamab brengitecan) Ph3 trial shows 40% reduced death risk in triple-negative breast cancer, Rallybio merges with Avenzo Therapeutics in reverse merger, backed by $215M private placement
Jun 1, 2026
🧬 Eli Lilly's Kelonia Therapeutics' (KLN-1010) shows 100% response rate in Ph1 relapsed or refractory multiple myeloma trial, Revolution Medicines' daraxonrasib nearly doubles survival in Ph3 metastatic pancreatic cancer with KRAS mutation, Gilead's TUB-040 (NaPi2b-targeting ADC) shows 61% tumor response in Ph1 platinum-resistant ovarian cancer trial
May 30, 2026
8 min read
Selling to Scientists & Technical Industries
May 29, 2026
3 min read
🧬 Pfizer, Innovent Biologics strike $10B cancer deal covering 12 ADC and multispecific antibody programs, $650M upfront, AstraZeneca's Imfinzi (durvalumab) wins FDA approval for BCG-naïve high-risk non-muscle-invasive bladder cancer after Ph3 win, Replimune resubmits RP1 melanoma BLA for third time following major FDA leadership shakeup
May 28, 2026
🧬 GSK, Ionis Pharmaceuticals' (bepirovirsen) achieves Ph3 functional cure in nearly 20% of chronic hepatitis B patients, AbbVie's Decnupaz wins FDA approval for blastic plasmacytoid dendritic cell neoplasm, targeting CD123 in Ph1/2, Secretome Therapeutics raises $30M Series A to advance cardiac cell therapies pipeline
May 27, 2026
🧬 Outlook Therapeutics' Lytenava (bevacizumab) gains FDA appeal win for wet age-related macular degeneration, AstraZeneca's (camizestrant) FDA review delayed after advisory committee rejects Ph3 data for HR-positive breast cancer, Astellas unveils five-year growth strategy to offset Xtandi patent expiry through pipeline acquisitions
May 26, 2026
🧬 Eli Lilly to acquire Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8B to build infectious disease pipeline
May 22, 2026
🧬 Eli Lilly's (retatrutide) Ph3 TRIUMPH-1 delivers bariatric surgery–level weight loss in obesity patients, Research Alliance III raises $75M SPAC IPO, targeting China-based biotech merger, Merck & Co., Kelun-Biotech's (sacituzumab tirumotecan) plus Keytruda cuts progression risk 65% in Ph3 non-small cell lung cancer
May 21, 2026
🧬 Parabilis Medicines files for IPO after raising $800M, targeting "undruggable" oncology proteins, Eli Lilly acquires Engage Bio for up to $202M to expand nonviral DNA delivery platform, Bristol Myers Squibb, Anthropic partner to deploy Claude AI across drug development operations
May 20, 2026
🧬 UCB's Bimzelx (bimekizumab) outperforms Skyrizi in Ph3 head-to-head trial for psoriatic arthritis, Incyte, Edison Scientific partner to deploy Kosmos AI across drug discovery and R&D workflows, Mentari Therapeutics goes public via reverse merger with InMed Pharmaceuticals, raising $290M for migraine pipeline
May 19, 2026
🧬 Bristol Myers Squibb weighs $1B Houston manufacturing plant that could employ 500 people, Merck & Co.'s (sacituzumab tirumotecan) hits Ph3 mark in endometrial cancer, beating chemotherapy in survival outcomes, Full-Life Technologies raises $150M Series D, advancing radiotherapeutics pipeline and Belgium manufacturing
May 18, 2026
🧬 Eisai projects $905M in Leqembi revenues for fiscal 2026, driven by subcutaneous auto-injector launch, Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) gains FDA approval for two HER2-positive breast cancer indications following Ph3 data, FDA's CDER, CBER acting directors and chief of staff ousted following Commissioner Makary's departure
